Cd40 Ligand Therapy of Lymphoma Patients

Article Tools SPECIAL DEPARTMENTS Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.2001.19.23.4351 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 11731523 Cd40 Ligand Therapy of Lymphoma Patients Anas YounesxAnas YounesSearch for articles by this author Robert H. VonderheidexRobert H. VonderheideSearch for articles by this author , Janice P. DutcherxJanice P. DutcherSearch for articles by this author , Jeanne E. AndersonxJeanne E. AndersonSearch for articles by this author , S. Gail EckhardtxS. Gail EckhardtSearch for articles by this author , Dania A. CaronxDania A. CaronSearch for articles by this author , John G. GribbenxJohn G. GribbenSearch for articles by this author Show More University of Texas M.D. Anderson Cancer Center, Houston, TXDana-Farber Cancer Institute, Harvard Medical School, Boston, MANew York Medical College, Our Lady of Mercy Cancer Center, Bronx, NYInstitute for Drug Development, San Antonio, TXImmunex Corporation, Seattle, WADana-Farber Cancer Institute, Harvard Medical School, Boston, MA https://doi.org/10.1200/JCO.2001.19.23.4351 First Page Full Text PDF Figures and Tables © 2001 by American Society of Clinical OncologyjcoJ Clin OncolJournal of Clinical OncologyJCO0732-183X1527-7755American Society of Clinical OncologyResponse01122001In Reply:Dr Younes raises several interesting questions regarding our phase I study of recombinant human CD40 ligand (rhuCD40L) in cancer patients.1 Table 1 outlines further information regarding the nine patients with non-Hodgkin’s lymphoma (NHL) treated with this agent. Further Clinical Data for Nine NHL Patients Treated With rhuCD40L Further Clinical Data for Nine NHL Patients Treated With rhuCD40LPatient No.Age (years)/SexrhuCD40L dose (mg/kg/d)No. of CoursesHistology*Treatment Received After rhuCD40LClinical Follow-Up†*Lymphomas were classified according to the Working Formulation, not the Revised European-American Lymphoma classification. All patients had B-cell NHL except patient no. 1053, who had a T-cell NHL.†Patients were followed for treatment history and survival status at 3, 6, 9, and 12 months after the last course of rhuCD40L.105152 /Male0.051Diffuse, mixed small and large cellsChemotherapy ImmunotherapyAlive at 12 months105243 /Female0.051Diffuse large cellChemotherapyDead at 3 months105352 /Female0.052Large-cell immunoblasticChemotherapyDead at 9 months205153 /Male0.102Diffuse large cellImmunotherapyDead at 6 months205222 /Male0.101Diffuse large cellChemotherapy ImmunotherapyDead at 9 months205356 /Female0.101Diffuse large cellUnknownLost to follow-up255171 /Male0.151Transformed to intermediate gradeChemotherapy ImmunotherapyDead at 9 months255267 /Female0.151Transformed to intermediate gradeChemotherapy ImmunotherapyAlive at 12 months255358 /Male0.152Diffuse, small cleaved cellChemotherapy ImmunotherapyAlive at 12 monthsThe patient with a partial response was a 52-year-old woman with large-cell immunoblastic T-cell lymphoma who at study entry had progressive disease (multiple skin lesions and lymphadenopathy). She had previously received chemotherapy, radiation therapy, and cytokine therapy with varying clinical responses, including prior partial responses and one complete response to radiation therapy. One month before study entry, she had progressive disease despite 2-deoxycoformycin. After the first course of rhuCD40L, the patient achieved a partial response, as evidenced by regression of skin lesions and reduced lymphadenopathy. After receiving a second course of rhuCD40L, the patient developed tiny, new skin lesions and a bone marrow biopsy showed relapse of her T-cell NHL. The patient was subsequently treated with chemotherapy but had died by the time of the 9-month poststudy follow-up. Tumor cell CD40 expression was not evaluated in this patient. Among the other NHL patients, six of eight patients had progressive disease after a single course of rhuCD40L, and two patients (nos. 2051 and 2553, Table 1) had stable disease after one course but progressive disease after two courses. Serum CD40L levels were not measured.Overall, we believe the data do not suggest that treatment of NHL patients with rhCD40L at this schedule resulted in acceleration of progressive disease.REFERENCE1. Vonderheide RH, Dutcher JP, Anderson JE, et al: Phase I study of recombinant human CD40 ligand in cancer patients. J Clin Oncol 19:: 3280,2001-3287, Link, Google Scholar